Growth rates of genetically defined renal tumors: Implications for active surveillance and intervention

Mark W. Ball, Julie Y. An, Patrick T. Gomella, Rabindra Gautam, Christopher J. Ricketts, Cathy D. Vocke, Laura S. Schmidt, Maria J. Merino, Ramaprasad Srinivasan, Ashkan A. Malayeri, Adam R. Metwalli, W. Marston Linehan

Research output: Contribution to journalArticle

Abstract

PURPOSE Published series of growth rates of renal tumors on active surveillance largely consist of tumors without pathologic or genetic data. Growth kinetics of genetically defined renal tumors are not well known. Here, we evaluate the growth of genetically defined renal tumors and their association with patient clinical and genetic characteristics. PATIENTS AND METHODS We evaluated patients with an inherited kidney cancer susceptibility syndrome as a result of a pathologic germline alteration of VHL, MET, FLCN, or BAP1 with at least 1 solid renal mass managed with active surveillance at our institution. Tumor growth rates (GR) were calculated and patients were stratified by genetic alteration and other clinical and genetic factors to analyze differences in growth rates using linear regression and comparative statistics. RESULTS A total of 292 patients with 435 genetically defined tumors were identified, including 286 VHL-deficient, 91 FLCN-deficient, 52 MET-activated, and 6 BAP1-deficient tumors. There were significant differences in GRs when stratified by genetic alteration. BAP1-deficient tumors had the fastest median GR (0.6 cm/y; interquartile range [IQR], 0.57-0.68 cm/y), followed by VHL-deficient tumors (GR, 0.37 cm/y; IQR, 0.25-0.57 cm/y), FLCN-deficient tumors (GR, 0.10 cm/y; IQR, 0.04-0.24 cm/y), and tumors with MET activation (GR, 0.15 cm/y; IQR, 0.053-0.32 cm/y; P, .001). Tumors from the same patient had similar GRs. Younger age was independently associated with higher GR (P = .005). CONCLUSION In a cohort of genetically defined tumors, tumor growth rates varied in a clinically and statistically different manner according to genetic subtype. Rapid growth of BAP1-deficient tumors indicates that these patients should be managed with caution. The faster growth of tumors in younger patients may support more frequent imaging, whereas the slower growth of other tumors may support extended surveillance beyond annual imaging in some instances.

Original languageEnglish (US)
Pages (from-to)1146-1153
Number of pages8
JournalJournal of Clinical Oncology
Volume38
Issue number11
DOIs
StatePublished - Apr 10 2020
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Growth rates of genetically defined renal tumors: Implications for active surveillance and intervention'. Together they form a unique fingerprint.

  • Cite this

    Ball, M. W., An, J. Y., Gomella, P. T., Gautam, R., Ricketts, C. J., Vocke, C. D., Schmidt, L. S., Merino, M. J., Srinivasan, R., Malayeri, A. A., Metwalli, A. R., & Linehan, W. M. (2020). Growth rates of genetically defined renal tumors: Implications for active surveillance and intervention. Journal of Clinical Oncology, 38(11), 1146-1153. https://doi.org/10.1200/JCO.19.02263